Skip to content
OpenCapital
Get started

Neurocrine Biosciences NBIX Cash & Equivalents

Cash & Equivalents at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$9.57B-12.0%
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
$282.21M+29.6%
Crinetics Pharmaceuticals logo
Crinetics PharmaceuticalsCRNX
$115.14M+20.1%
Solid Biosciences Inc. logo
Solid Biosciences Inc.SLDB
$297.1M+41.1%
MapLight Therapeutics, Inc. logo
MapLight Therapeutics, Inc. MPLT
$55.71M—
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$882.02M+62.5%

Other financials

Income statement

See full
Revenue$814.5M+42.2%
Gross profit$800.7M+42.1%
Operating income$193.4M+719%
Net income$197.9M+2,405%
EPS (diluted)$1.91+2,287%

Balance sheet

See full
Total debt$463.5M-6.0%
Total equity$3.4B+34.4%
Total assets$4.9B+33.0%

Cash flow

See full
Operating cash flow$145.8M+125%
CapEx$9.1M-15.0%
Free cash flow$136.7M+153%

Valuation

See full
Market cap$17.3B+29.6%
Enterprise value$17.49B+28.9%
P/E25.9×-12.5×
P/S5.6×+0.3×

Profitability

See full
Gross margin98.2%-0.3pp
Operating margin25.4%+4.9pp
Net margin21.6%+8.9pp
FCF margin26.8%+6.4pp

Returns & leverage

See full
Return on equity22.5%+10.1pp
Debt / equity0.1×-0.1×
Current ratio2.9×-0.2×

Where this comes from

Reported directly by Neurocrine Biosciences in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The official record: Neurocrine Biosciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Neurocrine Biosciences's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Neurocrine Biosciences's cash & equivalents?
Neurocrine Biosciences (NBIX) reported cash & equivalents of $274.5M in Q1 2026.
How has Neurocrine Biosciences's cash & equivalents changed year-over-year?
Neurocrine Biosciences's cash & equivalents increased by 35.8% year-over-year, from $202.1M to $274.5M.
What is the long-term trend for Neurocrine Biosciences's cash & equivalents?
Over 5 years (2020 to 2025), Neurocrine Biosciences's cash & equivalents has grown at a 30.5% compound annual growth rate (CAGR), from $190.3M to $721M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.